Evidence map›Paper›PMID 8909259›Full record

ArticleThe American journal of pathology1996

Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations.

Y Yao, L Jin, A Fuchs, A Joseph, H M Hastings, I D Goldberg, E M Rosen

Abstract read
In one paragraph

Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 56 citations in OpenAlex.

  1. Cooperative Effect of OncogenicMolecular cancer therapeutics · 2019
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Y YaoDepartment of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
L Jin
A Fuchs
A Joseph
H M Hastings
I D Goldberg
E M Rosen
Long Island Jewish Medical Center · US

Funding

REGULATION OF SCATTER FACTOR EXPRESSION IN BREAST CANCERR01CA064869 · NCI · LONG ISLAND JEWISH MEDICAL CENTER · PI ROSEN, ELIOT M · 1994 to 1997
–
NCI NIH HHS CA-64869
6 · The paper itself

Abstract

Scatter factor (SF) is an invasogenic and angiogenic cytokine the cellular receptor of which is encoded by a proto-oncogene (c-met). We measured the immunoreactive SF content (nanograms of SF per milligram of protein) in tissue extracts from 166 breast cancers and correlated the values with various known prognostic parameters. Invasive cancers had nearly four times greater SF content than did ductal carcinoma in situ, and the difference was statistically significant (P < 0.02, two-tailed t-test). However, there were no significant differences in SF content among different histological types of invasive cancer. Invasive cancers that had spread to axillary lymph nodes exhibited higher SF content than did invasive cancers without regional spread (P < 0.02), but the difference in SF content between node-positive and node-negative tumors was not as great as that between invasive and ductal carcinoma in situ tumors. There was a trend toward increased SF content in larger primary tumors as compared with smaller tumors, but statistical comparison revealed borderline significance (0.05 < P < 1.0). There was no significant correlation between SF content and other parameters, including estrogen receptor, progesterone receptor, DNA ploidy, S phase, or Scarff-Bloom-Richardson score. We also measured the content of von Willebrand factor (a marker of blood vessels) and interleukin-1 beta (a pro-inflammatory cytokine) in the same tumor extracts. SF content showed a strong positive correlation with von Willebrand factor content (P < 0.001) but did not appear to be correlated with interleukin-1 beta. These findings suggest that SF is correlated with several other clinicopathological indicators of aggressive tumor behavior, consistent with the hypothesis that SF is a biological factor that may play a role in breast cancer pathogenesis.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinomaDNA, NeoplasmEnzyme-Linked Immunosorbent AssayFlow CytometryHepatocyte Growth FactorHumansInterleukin-1Lymphatic MetastasisNeoplasm InvasivenessPrognosisProto-Oncogene Masvon Willebrand FactorBiomarkers, TumorDNA, NeoplasmHepatocyte Growth FactorInterleukin-1MAS1 protein, humanProto-Oncogene Masvon Willebrand Factor

Identifiers

PMID8909259
PMCPMC1865271
OpenAlexW2363087604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.